Edward is the Chief Medical Officer (CMO) of Third Harmonic Bio where he oversees the clinical development strategy for the company. Edward has extensive experience in clinical development, translational medicine, and clinical strategy, including broad experience in early- to late-stage and post-marketing products.
Edward joined Third Harmonic Bio from Locanabio, where he served as CMO. Prior to Locanabio, Edward was Site Lead and Division Head of Medical and Development for Astellas Gene Therapies (formerly Audentes Therapeutics). Prior to Astellas’ acquisition of Audentes, he served as CMO and Senior Vice President of Audentes Therapeutics, where he led functions including clinical development and operations, medical affairs, regulatory, drug safety, and patient advocacy. Before Audentes, Edward served as CMO of Sangamo Therapeutics. Earlier in his career, he was a Medical Director at Genentech, Inc. (now a member of the Roche Group) where he led clinical development programs for XOLAIR® (omalizumab) for the treatment of chronic urticaria and allergic asthma.
Edward earned a M.D. from the University of California, San Francisco, completed his residency in Internal Medicine at the University of Michigan and his fellowship in Clinical Immunology and Allergic Diseases at Johns Hopkins School of Medicine. He earned a B.S. degree in biology from Duke University.
XOLAIR® is a registered trademark of Novartis AG.
What is Edward R. Conner's net worth?
The estimated net worth of Edward R. Conner is at least $26.90 thousand as of December 6th, 2017. Conner owns 5,000 shares of Third Harmonic Bio stock worth more than $26,900 as of December 5th. This net worth estimate does not reflect any other assets that Conner may own. Learn More about Edward R. Conner's net worth.
How do I contact Edward R. Conner?
Has Edward R. Conner been buying or selling shares of Third Harmonic Bio?
Who are Third Harmonic Bio's active insiders?
